PFO
EBS icon

Pathstone Family Office’s Emergent Biosolutions EBS Stock Holding History

Pathstone Family Office’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,833
Closed -$164K – 1259
2023
Q1 		$164K Buy
+15,833
New +$191K ﹤0.01% 1108
2021
Q1 		– Sell
-7
Closed -$1K – 855
2020
Q4 		$1K Hold
7
– – ﹤0.01% 1081
2020
Q3 		$1K Sell
7
-7
-50% -$755 ﹤0.01% 733
2020
Q2 		$2K Buy
+14
New +$1.04K ﹤0.01% 625

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pathstone Family Office's EBS Position: Q2 2023 in Review

Pathstone Family Office sold out of Emergent Biosolutions (EBS) in Q2 2023, closing a stake of 15,833 shares — an estimated $164K sold.

Pathstone Family Office first reported a position in EBS in Q2 2020 and held it in 4 quarters. The position peaked at $164K in Q1 2023. 183 funds tracked by Wall St. Rank hold EBS as of Q2 2023.

  • Pathstone Family Office reported no remaining Emergent Biosolutions position as of Q2 2023 after selling out during the quarter.
  • Pathstone Family Office sold 15,833 Emergent Biosolutions shares in Q2 2023, an estimated $164K.
  • Pathstone Family Office first reported a position in Emergent Biosolutions in Q2 2020 and held it in 4 quarters.
  • Pathstone Family Office's Emergent Biosolutions position peaked at $164K in Q1 2023.
  • 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2023.

Based on Pathstone Family Office's 13F filing for Q2 2023, filed 14 Aug 2023.